Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.

p62 is a RNA-binding protein that was isolated by immunoscreening a cDNA expression library with autoantibodies from patients with hepatocellular carcinoma (HCC). This autoantigen binds to mRNA encoding insulin-like growth factor II, which has been found to be overexpressed in HCC and is tumorigenic in transgenic animals. Immunohistochemical analysis of HCC liver showed that 33% (9 of 27) exhibited readily detectable staining of p62 protein in the cytoplasm of all malignant cells in cancer nodules, whereas it was undetectable in adjacent nonmalignant liver cells. In addition one of two patients with cholangiocarcinoma expressed p62 in malignant bile duct epithelial cells. p62 expression was also detected in scattered cells in cirrhotic nodules in contrast to uniform expression in all cells in HCC nodules. In HCC nodules, p62 mRNA was also detected by reverse transcriptase-polymerase chain reaction analysis. Nine normal adult livers did not contain detectable p62 mRNA or p62 protein whereas five fetal livers were all positive for mRNA and protein. The observations show that p62 is developmentally regulated, expressed in fetal, but not in adult liver, and aberrantly expressed in HCC and could be playing a role in abnormal cell proliferation in HCC and cirrhosis by modulating expression of growth factors such as insulin-like growth factor II.

[1]  G. Dreyfuss,et al.  The pre-mRNA binding K protein contains a novel evolutionarily conserved motif. , 1993, Nucleic acids research.

[2]  G. Michalopoulos,et al.  Hepatocyte growth factor mRNA in human liver cirrhosis as evidenced by in situ hybridization. , 1996, Scandinavian journal of gastroenterology.

[3]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[4]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[5]  F. Nielsen,et al.  A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development , 1999, Molecular and Cellular Biology.

[6]  R. Singer,et al.  Characterization of a beta-actin mRNA zipcode-binding protein , 1997, Molecular and cellular biology.

[7]  N. Betz,et al.  The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. , 1998, Nucleic acids research.

[8]  Xuan Peng,et al.  A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma , 1999, The Journal of experimental medicine.

[9]  A. Pastore,et al.  Novel RNA-binding motif: the KH module. , 1999, Biopolymers.

[10]  Anne Wright,et al.  Cloning and Characterization of HuR, a Ubiquitously Expressed Elav-like Protein (*) , 1996, The Journal of Biological Chemistry.

[11]  E. Chan,et al.  Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjögren's syndrome. , 1997, Arthritis and rheumatism.

[12]  J. Mate,et al.  Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: a fine-needle aspiration cytology and biopsy study. , 1993, Human pathology.

[13]  J. Keene,et al.  A common RNA recognition motif identified within a defined U1 RNA binding domain of the 70K U1 snRNP protein , 1989, Cell.

[14]  K. Iatrou,et al.  Trans-activation of a cell housekeeping gene promoter by the IE1 gene product of baculoviruses. , 1996, Virology.

[15]  A. Shyu,et al.  RNA stabilization by the AU‐rich element binding protein, HuR, an ELAV protein , 1998, The EMBO journal.

[16]  G. Dreyfuss,et al.  RNA-binding proteins as regulators of gene expression. , 1997, Current opinion in genetics & development.

[17]  Toshitaka Nakamura,et al.  Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. , 1998, The American journal of pathology.

[18]  I. de Sio,et al.  Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus–related chronic hepatitis, cirrhosis, and hepatocellular carcinoma , 1996, Hepatology.

[19]  James O. Deshler,et al.  A highly conserved RNA-binding protein for cytoplasmic mRNA localization in vertebrates , 1998, Current Biology.

[20]  J. Keene,et al.  Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. , 1997, American journal of human genetics.

[21]  M. Rosenblum,et al.  Anti‐Hu-Associated Paraneoplastic Encephalomyelitis/Sensory Neuronopathy A Clinical Study of 71 Patients , 1992, Medicine.

[22]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[23]  F. Chisari,et al.  Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. , 1992, Cancer research.

[24]  C. Rogler,et al.  Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. , 1994, Journal of Biological Chemistry.

[25]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[26]  C. Osborne,et al.  Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. , 1989, Molecular endocrinology.

[27]  J. Keene,et al.  Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAs. , 1993, Molecular and cellular biology.

[28]  M. Eccles,et al.  Expression of insulin-like growth factor-II transcripts in Wilms' tumour , 1985, Nature.

[29]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[30]  T. Nakamura,et al.  Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Nussbaum,et al.  Essential role for KH domains in RNA binding: Impaired RNA binding by a mutation in the KH domain of FMR1 that causes fragile X syndrome , 1994, Cell.

[32]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Steitz,et al.  Overexpression of HuR, a nuclear–cytoplasmic shuttling protein, increases the in vivo stability of ARE‐containing mRNAs , 1998, The EMBO journal.

[34]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[35]  H. Friess,et al.  Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein , 1997, Oncogene.

[36]  J. Keene.  Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Hill,et al.  Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) , 1995, British Journal of Cancer.

[38]  J. Mulshine,et al.  Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. , 1998, American journal of respiratory cell and molecular biology.

[39]  A. Git,et al.  RNA-binding protein conserved in both microtubule- and microfilament-based RNA localization. , 1998, Genes & development.

[40]  S. Seki,et al.  Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde. , 1992, The American journal of pathology.

[41]  J. Scott,et al.  Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues , 1985, Nature.

[42]  A. Ullrich,et al.  Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. , 1988, Cancer research.